Os9) and the Hypoxia Response Gene, Hypoxia Inducible Factor 1 (Hif1) Alpha, in Kidney Tubular Cells
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Metalloproteases Meprin Α and Meprin Β: Unique Enzymes In
Biochem. J. (2013) 450, 253–264 (Printed in Great Britain) doi:10.1042/BJ20121751 253 REVIEW ARTICLE The metalloproteases meprin α and meprin β: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis Claudia BRODER and Christoph BECKER-PAULY1 Institute of Biochemistry, Unit for Degradomics of the Protease Web, University of Kiel, Rudolf-Hober-Str.¨ 1, Kiel 24118, Germany The metalloproteases meprin α and meprin β exhibit structural peptides is thought to be the major cause of the neurodegenerative and functional features that are unique among all extracellular Alzheimer’s disease. On the other hand, ADAM10 (a disintegrin proteases. Although meprins were discovered more than 30 years and metalloprotease domain 10), which is the constitutive α- ago, their precise substrates and physiological roles have been secretase, was shown to be activated by meprin β, which is itself elusive. Both enzymes were originally found to be highly shed from the cell surface by ADAM10. In skin, both meprins expressed in kidney and intestine, which focused research are overexpressed in fibrotic tumours, characterized by massive on these particular tissues and associated pathologies. Only accumulation of fibrillar collagens. Indeed, procollagen III is recently it has become evident that meprins exhibit a much processed to its mature form by meprin α and meprin β,an broader expression pattern, implicating functions in angiogenesis, essential step in collagen fibril assembly. The recently solved cancer, inflammation, fibrosis and neurodegenerative diseases. crystal structure of meprin β and the unique cleavage specificity Different animal models, as well as proteomics approaches for of these proteases identified by proteomics will help to generate the identification of protease substrates, have helped to reveal specific inhibitors that could be used as therapeutics to target more precise molecular signalling events mediated by meprin meprins under certain pathological conditions. -
Genome Sequence of the Progenitor of the Wheat D Genome Aegilops Tauschii Ming-Cheng Luo1*, Yong Q
OPEN LETTER doi:10.1038/nature24486 Genome sequence of the progenitor of the wheat D genome Aegilops tauschii Ming-Cheng Luo1*, Yong Q. Gu2*, Daniela Puiu3*, Hao Wang4,5,6*, Sven O. Twardziok7*, Karin R. Deal1, Naxin Huo1,2, Tingting Zhu1, Le Wang1, Yi Wang1,2, Patrick E. McGuire1, Shuyang Liu1, Hai Long1, Ramesh K. Ramasamy1, Juan C. Rodriguez1, Sonny L. Van1, Luxia Yuan1, Zhenzhong Wang1,8, Zhiqiang Xia1, Lichan Xiao1, Olin D. Anderson2, Shuhong Ouyang2,8, Yong Liang2,8, Aleksey V. Zimin3, Geo Pertea3, Peng Qi4,5, Jeffrey L. Bennetzen6, Xiongtao Dai9, Matthew W. Dawson9, Hans-Georg Müller9, Karl Kugler7, Lorena Rivarola-Duarte7, Manuel Spannagl7, Klaus F. X. Mayer7,10, Fu-Hao Lu11, Michael W. Bevan11, Philippe Leroy12, Pingchuan Li13, Frank M. You13, Qixin Sun8, Zhiyong Liu8, Eric Lyons14, Thomas Wicker15, Steven L. Salzberg3,16, Katrien M. Devos4,5 & Jan Dvořák1 Aegilops tauschii is the diploid progenitor of the D genome of We conclude therefore that the size of the Ae. tauschii genome is about hexaploid wheat1 (Triticum aestivum, genomes AABBDD) and 4.3 Gb. an important genetic resource for wheat2–4. The large size and To assess the accuracy of our assembly, sequences of 195 inde- highly repetitive nature of the Ae. tauschii genome has until now pendently sequenced and assembled AL8/78 BAC clones8, which precluded the development of a reference-quality genome sequence5. contained 25,540,177 bp in 2,405 unordered contigs, were aligned to Here we use an array of advanced technologies, including ordered- Aet v3.0. Five contigs failed to align and six extended partly into gaps, clone genome sequencing, whole-genome shotgun sequencing, accounting for 0.25% of the total length of the contigs. -
Discovery and Optimization of Selective Inhibitors of Meprin Α (Part II)
pharmaceuticals Article Discovery and Optimization of Selective Inhibitors of Meprin α (Part II) Chao Wang 1,2, Juan Diez 3, Hajeung Park 1, Christoph Becker-Pauly 4 , Gregg B. Fields 5 , Timothy P. Spicer 1,6, Louis D. Scampavia 1,6, Dmitriy Minond 2,7 and Thomas D. Bannister 1,2,* 1 Department of Molecular Medicine, Scripps Research, Jupiter, FL 33458, USA; [email protected] (C.W.); [email protected] (H.P.); [email protected] (T.P.S.); [email protected] (L.D.S.) 2 Department of Chemistry, Scripps Research, Jupiter, FL 33458, USA; [email protected] 3 Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR r.605, Fort Lauderdale, FL 33314, USA; [email protected] 4 The Scripps Research Molecular Screening Center, Scripps Research, Jupiter, FL 33458, USA; [email protected] 5 Unit for Degradomics of the Protease Web, Institute of Biochemistry, University of Kiel, Rudolf-Höber-Str.1, 24118 Kiel, Germany; fi[email protected] 6 Department of Chemistry & Biochemistry and I-HEALTH, Florida Atlantic University, 5353 Parkside Drive, Jupiter, FL 33458, USA 7 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, 3301 College Avenue, Fort Lauderdale, FL 33314, USA * Correspondence: [email protected] Abstract: Meprin α is a zinc metalloproteinase (metzincin) that has been implicated in multiple diseases, including fibrosis and cancers. It has proven difficult to find small molecules that are capable Citation: Wang, C.; Diez, J.; Park, H.; of selectively inhibiting meprin α, or its close relative meprin β, over numerous other metzincins Becker-Pauly, C.; Fields, G.B.; Spicer, which, if inhibited, would elicit unwanted effects. -
Metalloprotease Meprinb in Rat Kidney: Glomerular Localization and Differential Expression in Glomerulonephritis
Metalloprotease Meprinb in Rat Kidney: Glomerular Localization and Differential Expression in Glomerulonephritis Beatrice Oneda1., Nade`ge Lods1., Daniel Lottaz1¤, Christoph Becker-Pauly2, Walter Sto¨ cker2, Jeffrey Pippin3, Maya Huguenin1, Daniel Ambort1, Hans-Peter Marti4, Erwin E. Sterchi1* 1 Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland, 2 Institute of Zoology, Johannes Gutenberg University, Mainz, Germany, 3 Division of Nephrology, University of Washington, Seattle, Washington, United States of America, 4 Division of Nephrology/Hypertension, Inselspital, University of Bern, Bern, Switzerland Abstract Meprin (EC 3.4.24.18) is an oligomeric metalloendopeptidase found in microvillar membranes of kidney proximal tubular epithelial cells. Here, we present the first report on the expression of meprinb in rat glomerular epithelial cells and suggest a potential involvement in experimental glomerular disease. We detected meprinb in glomeruli of immunostained rat kidney sections on the protein level and by quantitative RT-PCR of laser-capture microdissected glomeruli on the mRNA level. Using immuno-gold staining we identified the membrane of podocyte foot processes as the main site of meprinb expression. The glomerular meprinb expression pattern was altered in anti-Thy 1.1 and passive Heymann nephritis (PHN). In addition, the meprinb staining pattern in the latter was reminiscent of immunostaining with the sheep anti-Fx1A antiserum, commonly used in PHN induction. Using Western blot and immunoprecipitation assays we demonstrated that meprinb is recognized by Fx1A antiserum and may therefore represent an auto-antigen in PHN. In anti-Thy 1.1 glomerulonephritis we observed a striking redistribution of meprinb in tubular epithelial cells from the apical to the basolateral side and the cytosol. -
Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling
www.nature.com/scientificreports OPEN Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Received: 07 October 2016 Accepted: 03 February 2017 Trans-Signaling Published: 09 March 2017 Philipp Arnold1, Inga Boll2, Michelle Rothaug2, Neele Schumacher2, Frederike Schmidt2, Rielana Wichert2, Janna Schneppenheim1, Juliane Lokau2, Ute Pickhinke2, Tomas Koudelka3, Andreas Tholey3, Björn Rabe2, Jürgen Scheller4, Ralph Lucius1, Christoph Garbers2, Stefan Rose-John2 & Christoph Becker-Pauly2 Soluble Interleukin-6 receptor (sIL-6R) mediated trans-signaling is an important pro-inflammatory stimulus associated with pathological conditions, such as arthritis, neurodegeneration and inflammatory bowel disease. The sIL-6R is generated proteolytically from its membrane bound form and A Disintegrin And Metalloprotease (ADAM) 10 and 17 were shown to perform ectodomain shedding of the receptor in vitro and in vivo. However, under certain conditions not all sIL-6R could be assigned to ADAM10/17 activity. Here, we demonstrate that the IL-6R is a shedding substrate of soluble meprin α and membrane bound meprin β, resulting in bioactive sIL-6R that is capable of inducing IL-6 trans- signaling. We determined cleavage within the N-terminal part of the IL-6R stalk region, distinct from the cleavage site reported for ADAM10/17. Interestingly, meprin β can be shed from the cell surface by ADAM10/17 and the observation that soluble meprin β is not capable of shedding the IL-6R suggests a regulatory mechanism towards trans-signaling. Additionally, we observed a significant negative correlation of meprin β expression and IL-6R levels on human granulocytes, providing evidence for in vivo function of this proteolytic interaction. -
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Published OnlineFirst February 21, 2013; DOI: 10.1158/2159-8290.CD-12-0418 RESEARCH ARTICLE Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition Alexandre Puissant1,3, Stacey M. Frumm1,3, Gabriela Alexe1,3,5,6, Christopher F. Bassil1,3, Jun Qi2, Yvan H. Chanthery8, Erin A. Nekritz8, Rhamy Zeid2, William Clay Gustafson8, Patricia Greninger7, Matthew J. Garnett10, Ultan McDermott10, Cyril H. Benes7, Andrew L. Kung1,3, William A. Weiss8,9, James E. Bradner2,4, and Kimberly Stegmaier1,3,6 Downloaded from cancerdiscovery.aacrjournals.org on October 2, 2021. © 2013 American Association for Cancer Research. 15-CD-12-0418_p308-323.indd 1 22/02/13 12:15 AM Published OnlineFirst February 21, 2013; DOI: 10.1158/2159-8290.CD-12-0418 A BSTRACT Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically defined cancer cell lines using a prototypical inhibitor of BET bromodomains. Integration of genetic features with chemosensitivity data revealed a robust correlation between MYCN amplification and sensitivity to bromodomain inhibition. We characterized the mechanistic and translational significance of this finding in neuroblastoma, a childhood cancer with frequent amplification of MYCN. Genome-wide expression analysis showed downregulation of the MYCN transcriptional program accompanied by suppression of MYCN transcription. Functionally, bromodomain-mediated inhibition of MYCN impaired growth and induced apoptosis in neuroblastoma. BRD4 knockdown phenocopied these effects, establishing BET bromodomains as transcriptional regulators of MYCN. BET inhibition conferred a significant survival advantage in 3 in vivo neuroblastoma models, providing a compelling rationale for developing BET bro- modomain inhibitors in patients with neuroblastoma. -
(10) Patent No.: US 8119385 B2
US008119385B2 (12) United States Patent (10) Patent No.: US 8,119,385 B2 Mathur et al. (45) Date of Patent: Feb. 21, 2012 (54) NUCLEICACIDS AND PROTEINS AND (52) U.S. Cl. ........................................ 435/212:530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search ........................ None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Houston, TX (US) OTHER PUBLICATIONS c Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (*) Notice: Subject to any disclaimer, the term of this bor New York, 2001, pp. 382-393.* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 689 days. Isolates of Pseudomonas aeruginosa” J. Bacteriol. (2003) 185: 1316 1325. (21) Appl. No.: 11/817,403 Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. 2002. (22) PCT Fled: Mar. 3, 2006 Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (86). PCT No.: PCT/US2OO6/OOT642 toxicology” Toxicol. Lett. (2000) 1.12: 365-370. S371 (c)(1), * cited by examiner (2), (4) Date: May 7, 2008 Primary Examiner — James Martinell (87) PCT Pub. No.: WO2006/096527 (74) Attorney, Agent, or Firm — Kalim S. Fuzail PCT Pub. Date: Sep. 14, 2006 (57) ABSTRACT (65) Prior Publication Data The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides US 201O/OO11456A1 Jan. 14, 2010 encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. -
Bioinformatics Integrated Analysis to Investigate Candidate Biomarkers and Associated Metabolites in Osteosarcoma
Wang et al. Journal of Orthopaedic Surgery and Research (2021) 16:432 https://doi.org/10.1186/s13018-021-02578-0 RESEARCH ARTICLE Open Access Bioinformatics integrated analysis to investigate candidate biomarkers and associated metabolites in osteosarcoma Jun Wang, Mingzhi Gong, Zhenggang Xiong, Yangyang Zhao and Deguo Xing* Abstract Background: This study hoped to explore the potential biomarkers and associated metabolites during osteosarcoma (OS) progression based on bioinformatics integrated analysis. Methods: Gene expression profiles of GSE28424, including 19 human OS cell lines (OS group) and 4 human normal long bone tissue samples (control group), were downloaded. The differentially expressed genes (DEGs) in OS vs. control were investigated. The enrichment investigation was performed based on DEGs, followed by protein–protein interaction network analysis. Then, the feature genes associated with OS were explored, followed by survival analysis to reveal prognostic genes. The qRT-PCR assay was performed to test the expression of these genes. Finally, the OS- associated metabolites and disease-metabolic network were further investigated. Results: Totally, 357 DEGs were revealed between the OS vs. control groups. These DEGs, such as CXCL12, were mainly involved in functions like leukocyte migration. Then, totally, 38 feature genes were explored, of which 8 genes showed significant associations with the survival of patients. High expression of CXCL12, CEBPA, SPARCL1, CAT, TUBA1A, and ALDH1A1 was associated with longer survival time, while high expression of CFLAR and STC2 was associated with poor survival. Finally, a disease-metabolic network was constructed with 25 nodes including two disease-associated metabolites cyclophosphamide and bisphenol A (BPA). BPA showed interactions with multiple prognosis-related genes, such as CXCL12 and STC2. -
Differential Regulation of Metzincins in Experimental Chronic Renal Allograft
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector original article http://www.kidney-international.org & 2006 International Society of Nephrology Differential regulation of metzincins in experimental chronic renal allograft rejection: Potential markers and novel therapeutic targets CC Berthier1,2,8, N Lods1,8, SA Joosten3, C van Kooten3, D Leppert4, RLP Lindberg4, A Kappeler5, F Raulf6, EE Sterchi7, D Lottaz7 and H-P Marti1 1Division of Nephrology/Hypertension, Inselspital, University of Bern, Bern, Switzerland; 2Division of Nephrology, University Hospital of Zu¨rich, Zu¨rich, Switzerland; 3Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands; 4Department of Neurology, University of Basel, Basel, Switzerland; 5Institute of Pathology, University of Bern, Bern, Switzerland; 6Department of Transplantation, Novartis Institutes of BioMedical Research, Basel, Switzerland and 7Institute of Biochemistry and Molecular Biology, University of Bern, Bern, Switzerland Chronic renal allograft rejection is characterized by chronic renal allograft rejection. Thus, an altered pattern of alterations in the extracellular matrix compartment and in metzincins may represent novel diagnostic markers and the proliferation of various cell types. These features are possibly may provide novel targets for future therapeutic controlled, in part by the metzincin superfamily of interventions. metallo-endopeptidases, including matrix metalloproteinases Kidney International -
MEP1A Allele for Meprin a Metalloprotease Is a Susceptibility Gene for Inflammatory Bowel Disease
ARTICLES nature publishing group See COMMENTARY page XX MEP1A allele for meprin A metalloprotease is a susceptibility gene for inflammatory bowel disease S B a n e r j e e 1 , 8 , B O n e d a 2 , 8 , L M Ya p 3 , 9 , D P J e w e l l 4 , G L M a t t e r s 1 , L R F it5 z p a , t r ic k F 6 S e , ib o l dE E 2 , S t e r c h i T A h m a d 7 , D L o t t a z 2,10 a n d J S B o n d 1 The MEP1A gene, located on human chromosome 6p (mouse chromosome 17) in a susceptibility region for inflammatory bowel disease (IBD), encodes the -subunit of metalloproteinase meprin A, which is expressed in the intestinal epithelium. This study shows a genetic association of MEP1A with IBD in a cohort of ulcerative colitis (UC) patients. There were four single-nucleotide polymorphisms in the coding region (P = 0.0012 – 0.04), and one in the 3 Ј -untranslated region ( P = 2 × 10 − 7 ) that displayed associations with UC. Moreover, meprin- mRNA was decreased in inflamed mucosa of IBD patients. Meprin- knockout mice exhibited a more severe intestinal injury and inflammation than their wild-type counterparts following oral administration of dextran sulfate sodium. Collectively, the data implicate MEP1A as a UC susceptibility gene and indicate that decreased meprin- expression is associated with intestinal inflammation in IBD patients and in a mouse experimental model of IBD. -
Functional and Structural Insights Into Astacin Metallopeptidases
Biol. Chem., Vol. 393, pp. 1027–1041, October 2012 • Copyright © by Walter de Gruyter • Berlin • Boston. DOI 10.1515/hsz-2012-0149 Review Functional and structural insights into astacin metallopeptidases F. Xavier Gomis-R ü th 1, *, Sergio Trillo-Muyo 1 Keywords: bone morphogenetic protein; catalytic domain; and Walter St ö cker 2, * meprin; metzincin; tolloid; zinc metallopeptidase. 1 Proteolysis Lab , Molecular Biology Institute of Barcelona, CSIC, Barcelona Science Park, Helix Building, c/Baldiri Reixac, 15-21, E-08028 Barcelona , Spain Introduction: a short historical background 2 Institute of Zoology , Cell and Matrix Biology, Johannes Gutenberg University, Johannes-von-M ü ller-Weg 6, The fi rst report on the digestive protease astacin from the D-55128 Mainz , Germany European freshwater crayfi sh, Astacus astacus L. – then termed ‘ crayfi sh small-molecule protease ’ or ‘ Astacus pro- * Corresponding authors tease ’ – dates back to the late 1960s (Sonneborn et al. , 1969 ). e-mail: [email protected]; [email protected] Protein sequencing by Zwilling and co-workers in the 1980s did not reveal homology to any other protein (Titani et al. , Abstract 1987 ). Shortly after, the enzyme was identifi ed as a zinc met- allopeptidase (St ö cker et al., 1988 ), and other family mem- The astacins are a family of multi-domain metallopepti- bers emerged. The fi rst of these was bone morphogenetic β dases with manifold functions in metabolism. They are protein 1 (BMP1), a protease co-purifi ed with TGF -like either secreted or membrane-anchored and are regulated growth factors termed bone morphogenetic proteins due by being synthesized as inactive zymogens and also by co- to their capacity to induce ectopic bone formation in mice localizing protein inhibitors. -
A Genome-Wide Association Study
ISSN (Online) 2287-3406 Journal of Life Science 2021 Vol. 31. No. 6. 568~573 DOI : https://doi.org/10.5352/JLS.2021.31.6.568 - Note - The Association of Long Noncoding RNA LOC105372577 with Endoplasmic Reticulum Protein 29 Expression: A Genome-wide Association Study Soyeon Lee1, Kiang Kwon2, Younghwa Ko3 and O-Yu Kwon3* 1School of Systems Biomedical Science, College of Natural Sciences, Soongsil University, Seoul 06978, Korea 2Department of Clinical Laboratory Science, Wonkwang Health Science University, Iksan 54538, Korea 3Department of Anatomy & Cell Biology, College of Medicine, Chungnam National University, Daejeon 35015, Korea Received April 27, 2021 /Revised April 29, 2021 /Accepted April 30, 2021 This study identified genomic factors associated with endoplasmic reticulum protein (ERp)29 gene ex- pression in a genome-wide association study (GWAS) of genetic variants, including single-nucleotide polymorphisms (SNPs). In total, 373 European genes from the 1000 Genomes Project were analyzed. SNPs with an allelic frequency of less than or more than 5% were removed, resulting in 5,913,563 SNPs including in the analysis. The following expression quantitative trait loci (eQTL) from the long noncoding RNA LOC105372577 were strongly associated with ERp29 expression: rs6138266 (p<4.172e10), rs62193420 (p<1.173e10), and rs6138267 (p<2.041e10). These were strongly expressed in the testis and in the brain. The three eQTL were identified through a transcriptome-wide association study (TWAS) and showed a significant association with ERp29 and osteosarcoma amplified 9 (OS9) expression. Upstream sequences of rs6138266 were recognized by ChIP-seq data, while HaploReg was used to demonstrate how its regulatory DNA binds upstream of transcription factor 1 (USF1).